Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Combination immunotherapy of renal cell carcinoma: efficacy established in phase II trial

June 11, 1998

Excellent phase III results reported for bropirimine in CIS

June 11, 1998

Encouraging results reported for Cel-Sci's Multikine

June 11, 1998

Immunex's CD40 Ligand enters phase I

June 10, 1998

Initiation of late-stage Avicine clinical trial

June 9, 1998

Genzyme Molecular Oncology and Dana-Farber agreement for fusion cell technology

June 5, 1998

Vical reports initial results from gene-based immunotherapy for prostate cancer

June 4, 1998

FDA advisory committee recommends approval of Ontak for CTCL

June 3, 1998

European Commission clears rituximab for marketing in member countries

June 3, 1998

Idec receives patent protection for radioimmunotherapy

June 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.